Use of whole-body MRI to evaluate residual tumor burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer
British Journal of Radiology · 2026
DOI: 10.1093/bjr/tqag168 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, 2026. Verfasst von Claire Thompson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, United Kingdom. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Whole Body Imaging. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objectives
Treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded, with evidence supporting prostate radiotherapy in low-volume disease. However, evidence for consolidative radiotherapy to residual sites in patients rendered oligometastatic after systemic therapy is lacking. Advanced imaging with WB-MRI and PSMA PET/CT enables more accurate assessment of tumor burden and response.
Methods
This feasibility study assessed response to initial systemic treatment with an ARPI or docetaxel in 29 patients with polymetastatic (>5 metastases) HSPC. PSA and WB-MRI response using MET-RADS-P criteria were recorded.
Results
A total of 20/29 (69.0.%) of patients were down-risked to oligometastatic disease (≤5 sites) after a median of 5.5 (IQR 5-5.8) months, identified on WB-MRI. Median PSA was 0.2 ng/mL (IQR 0.1-0.7) in down-risked patients vs 1.5 ng/mL (IQR 1.1-84) in those not down-risked. Residual intraprostatic disease was seen in 55% (11/20) of down-risked patients.
Conclusions
Most patients were down-risked on WB-MRI, supporting the existence of an induced oligometastatic state and providing rationale for the STAR TRAP randomized trial (ISRCTN16448082), which will assess the role of consolidative radiotherapy in this setting. Advances in knowledge WB-MRI correlates with PSA response and shows potential as an imaging biomarker in mHSPC in this small feasibility study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, United Kingdom.
ORCID-Profile: Claire Thompson
Zitieren
APA
Thompson, C., Withey, S. J., Tunariu, N., Parker, C., Tree, A., Reid, A., Pathmanathan, A., & Murray, J. (2026). Use of whole-body MRI to evaluate residual tumor burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer. British Journal of Radiology. https://doi.org/10.1093/bjr/tqag168
Vancouver
Thompson C, Withey SJ, Tunariu N, Parker C, Tree A, Reid A, et al. Use of whole-body MRI to evaluate residual tumor burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer. British Journal of Radiology. 2026. doi:10.1093/bjr/tqag168
BibTeX
@article{Thompson2026,
author = {Thompson, Claire and Withey, Samuel J and Tunariu, Nina and Parker, Chris and Tree, Alison and Reid, Alison and Pathmanathan, Angela and Murray, Julia},
title = {Use of whole-body MRI to evaluate residual tumor burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer},
journal = {British Journal of Radiology},
year = {2026},
doi = {10.1093/bjr/tqag168}
}
EUVIMED